A Sweet Deal for Cats: SGLT-2 Inhibitors in Feline Diabetes (NYVET2025)

Presented by Peter Chapman

This session will introduce SGLT-2 inhibitors as an emerging therapeutic option for feline diabetes. Attendees will explore their mechanism of action, ideal patient selection, monitoring strategies, and potential risks such as euglycemic ketoacidosis. Using real-world case examples, the talk will highlight how these agents can complement or, in select cases, replace insulin therapy, offering improved owner compliance and patient quality of life.